Low immunogenicity of whole virion, verocell-derived, inactivated, pandemic influenza H1N1 vaccine in HIV-infected patients by Lagler, H et al.
POSTER PRESENTATION Open Access
Low immunogenicity of whole virion, verocell-
derived, inactivated, pandemic influenza H1N1
vaccine in HIV-infected patients
H Lagler
1, K Grabmeier-Pfistershammer
2*, V Touzeau-Römer
2, S Tobudic
1, A Rieger
2, H Burgmann
1
From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010
HIV infected individuals face an increased risk of serious
illness from influenza. Current guidelines recommend
vaccination of all HIV infected adults. Several studies
have analysed the immunogenicity of adjuvant H1N1
vaccines in these individuals. However, no such analysis
exists for Celvapan (Baxter), an inactivated H1N1 vac-
cine without adjuvants, derived from verocells and based
on whole virions. Celvapan contains A/California/07/
2009 (H1N1)v virus strain. Vaccination was provided in
two i.m. doses, at least three weeks apart. This vaccine
has been used widely in Austria during the recent H1N1
pandemic.
Adult HIV-1 infected individuals scheduled for H1N1
vaccination where included in this study. Serum samples
were taken before the first vaccination (baseline) and
after the second vaccination. Antibody titers were deter-
mined by hemagglutination inhibition (HAI) assay using
chicken red blood cells and the Influenza A/H1N1pdm
virus A/California/7/2009 (NIBSC 09/146). Clinical and
HIV-related data were taken from patient charts. Sero-
conversion was defined as a ≥4-fold increase in antibody
titer between the pre- and post vaccination serum, and
a post-vaccination titer of ≥1:40 was considered protec-
tive. 78 patients were included in the study. 42 patients
provided serum samples after the second vaccination. 74
% of the patients were male. Median age was 38.5 years.
21 patients had a VL below the limit of quantification
(BLQ) since more than 12 months, 27 patients received
currently HAART therapy with a VL BLQ. The median
CD4 cell count was 442 cell/mm
3 and the median CD4
nadir 209 cell/mm
3. 38 % of the patients seroconverted
after receiving both doses of the vaccine. Only 7 patients
had HAI titers <1:40 before vaccination; all of them
showed post-vaccination titers of >1:40. There was no
significant difference with regard to age, the recent CD4
cell count or the CD4 nadir between seroconverters and
non-responders and the share of patients with a recent
VL BLQ or a VL BLQ for at least 12 months was
roughly equal in both groups.
Seroconversion rates in HIV-infected individuals were
significantly lower compared to those in otherwise
healthy individuals in spite of a high percentage of indi-
viduals with well-controlled VL BLQ and high CD4 cell
counts. In addition, seroconversion rate for HIV-infected
individuals in this observational trial during 2009 pan-
demic flu season were lowert h a nt h o s er e c e n t l yp u b -
lished in studies using adjuvant H1N1 vaccines.
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